501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Achieves
THC
Breath Capture Milestone,
Comments on Patent Portfolio
The Cannabix Marijuana Breathalyzer is being developed to
provide
law enforcement and employers a tool to enforce public
safety.
Vancouver, British
Columbia -- July
24,
2019 -- InvestorsHub
NewsWire -- Cannabix
Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or
Cannabix") developer of the
Cannabix Marijuana Breathalyzer for law enforcement and the
workplace, is pleased to report that Company
scientists
have
developed
proprietary methods
resulting in the
achievement
of the highest
?9-tetrahydrocannabinol
("THC")
detection levels collected
from human breath
to
date.
Over
the last several months, Company
scientists
have studied the unique
chemical interactions of THC and cannabinoids in breath, and
developed
and
evaluated novel
methods to
efficiently
and practically capture
and
ionize THC
and
cannabinoid analytes
collected
from
several
different
subjects.
These
analytes are
typically
found
in extremely low quantities due to their
relatively low volatilities, requiring
an efficient
sampling
method.
The
Company's newly
developed methods
and
technologies
for
sample capture are
an
important milestone and represent
a significant
advancement in the
field of human breath studies.
These
novel capture methods could have implications for both
point-of-care
and lab-based
instruments
that
would provide real-time results from
breath
samples, targeting
analytes of a wide
range of volatilities.
The
Company continues to
expeditiously
conduct
trial testing to evaluate
the
sensitivity
and
accuracy of the instrument and to
collect data to determine
variance among test
subjects at its
Vancouver and
Florida development facilities using its
FAIMS
(field asymmetric waveform ion mobility spectrometry) THC detection
device.
Growing
Patent Portfolio
The
Company's patent portfolio includes an exclusive worldwide license
of University of Florida ("UF") US Patent 8,237,118 in the area of
breath analysis of controlled substances using
Partial
Ovoidal FAIMS Electrode (high field
asymmetric waveform ion mobility spectrometry). Additionally, the
Company has licensed patent pending technology from UF
(US
16/082220)
relating to using
FAIMS detection, and has
filed
its own
patent applications commencing
in 2015.
The
Company's technology has significantly progressed since its
original filings, and improvements
have been made to every aspect of the instrument
(in
particular related to Company's
originally filed US and
Canadian patent
application Nos. 14/689434
and 2887841).
New intellectual
property and trade secrets have been developed that will ultimately
supersede earlier patent applications. The
Company's intellectual
property is growing and
additional patent
applications will be filed in due course.
Additional
applications that are already pending include Canadian and US
applications directed to an intercept system (ignition
interlock device)
for
controlled substances (Nos. 3041860 and 16/344578).
An
ignition
interlock
device
requires a driver to blow into an installed device confirming the
driver is not impaired before the vehicle will start. Many
countries are requiring an ignition
interlock
device
as a
condition for drivers convicted of driving under the influence of
alcohol and drugs, especially repeat offenders.
The
Company
routinely receives official
correspondence related to its
pending patent applications
from
Canadian and US Patent and Trademark Offices. Such
correspondence requires
a
formal response from the Company to refine the application
to
address any objections raised by the offices. Such official
correspondence can be expected by
the Company as it is normal for patents to be initially refused
(even a few times) by the patent office.
The
Company is entitled to submit arguments and/or amend its claims in
order to address the Examiner's reasons for rejection to
secure
grant of a patent. As usual, Company
patent lawyers review the merits of
the Patent
Office's
comments and prepare and
file responses as required.
About
Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing durable,
portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects usage,
days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment
by THC
can be hazardous.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary
Statement Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.